natgillin/translations-raw huggingface dataset:
The storage system according to claim 1, further comprising additional vehicles arranged to move at the top level of the first grid structure and arranged to receive a storage bin from a storage cell at the top level of the first grid structure. 
Sustav za skladištenje sukladno jednom od prethodnih patentnih zahtjeva se dalje sastoji od dodatnih vozila postavljenih na način da se pomjeraju na najvišoj razini (20) prve strukture rešetke i postavljenih za prijem kontejnera za skladištenje sa stanica za skladištenje s najviše razine (20) prve strukture.
A method for inducing tolerance to an allergy in a subject with an allergy to a food allergen, said method comprising administering to said subject a probiotic, a prebiotic agent, and the food allergen or an antigenic component thereof, in an amount effective to induce tolerance to said food allergen, wherein the food allergen is a legume allergen, wherein the probiotic is a species of Lactobacillus selected from the group consisting of Lactobacillus acidophilus NCFM, Lactobacillus casei, Lactobacillus casei Shirota, Lactobacillus casei immunitas, Lactobacillus johnsonii, Lactococcus lactis, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus salivarius, and Lactobacillus helveticus, wherein the prebiotic agent is selected from the group consisting of an oligosaccharide and a fibre, and wherein the probiotic is administered to the subject in conjunction with the food allergen in the same formulation. The method of claim 29 wherein the probiotic is Lactobacillus rhamnosus. 
Upotreba probiotika i alergena hrane prema patentnom zahtjevu 9 gdje je probiotik iz vrste Lactobacillus. Upotreba probiotika i alergena hrane prema patentnom zahtjevu 10 gdje je Lactobacillus vrsta odabrana s liste koja se sastoji od Lactobacillus acidophilus NCFM, Lactobacillus casei, Lactobacillus casei Shirota, Lactobacillus casei immunitass, Lactobacillus johnsonii, Lactococcus lactis, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillu rhamnosus, Lactobacillus salivarius and Lactobacillus helvetirus. Upotreba probiotika i alergena hrane prema patentnom zahtjevu 11 gjde je probiotik Lactobacillus rhamnosus.
a domain (A) comprising said CD3-specific VL domain; 
(i) < domena (A) koja sadrži navedeni CD3-specifičnu VL domenu;
reacting a compound of formula (3) wherein 
(a) reakciju spoja formule (3) iRČK
The microfluidic device according to claim 1, said vent comprising a venting port functioning as a stop flow valve. The microfluidic device according to claim 1 characterized in that said first area of said first region comprises a reaction cell containing a first reagent capable of initiating clotting of said fluid medium. 
Mikrofluidički uređaj u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što navedeno drugo područje navedene druge regije se sastoji od reakcijske Ćelije (5b), koja sadrži reagens koji može inhibirati koagulaciju navedenog fluidnog medija.
The method of claim 1, wherein the patient is afflicted with, diagnosed with, or at risk of being afflicted with a disease or disorder selected from the group consisting of sarcopenia, cachexia, and muscle atrophy due to disuse or immobilization. 
Upotreba u skladu s patentnim zahtjevom 7, naznačena time, da je metabolički sindrom odabran iz skupine koju čine dijabetes, pretilost, prehrambeni poremećaji, atrofija organa, kronična opstruktivna plućna bolest i anoreksija.
77, pages 313-348. According to a preferred embodiment of the present invention, said process can be carried out in the presence of an inert organic solvent selected, for example, from: saturated aliphatic hydrocarbons such as, for example, butane, pentane, hexane, heptane, or mixtures thereof; saturated cycloaliphatic hydrocarbons such as cyclopentane, cyclohexane, or mixtures thereof; mono-olefins such as 1-butene, 2-butene, or mixtures thereof; aromatic hydrocarbons such as benzene, toluene, xylene, or mixtures thereof; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, trichloroethylene, perchloroethylene, 1,2-dichloroethane, chlorobenzene, bromobenzene, chlorotoluene, or mixtures thereof. 
Postupak u skladu s bilo kojim od patentnih zahtjeva od 9 do 15, naznačen time što se navedeni postupak provodi u prisutnosti inertnog organskog otapala, kojeg se bira između: zasićenih alifatskih ugljikovodika, poput butana, pentana, heksana, heptana, ili njihovih smjesa; zasićenih cikloalifatskih ugljikovodika, poput ciklopentana, cikloheksana, ili njihovih smjesa; monoolefina, poput 1-butena, 2-butena, ili njihovih smjesa; aromatskih ugljikovodika, poput benzena, toluena, ksilena, ili njihovih smjesa; halogeniranih ugljikovodika, poput metilen-klorida, kloroforma, ugljičnog tetraklorida, trikloretilena, perkloretilena, 1,2-dikloretana, klorbenzena, brombenzena, klortoluena, ili njihovih smjesa.
The procedure of the preceding claim, wherein the step of selecting the desired air flow value per linear metre comprises a sub-step of determining a desired value of air flow per linear metre in setting up operating conditions of the plant when using the heating plant of an environment, for example during a winter season, and/or a sub-step of determining a desired value of air flow per linear metre according to a design project in order not to generate ground currents and to obtain a diffusion of air by inductive effect, and/or a sub-step of determining a desired air flow value per linear metre in operating conditions by means of one or more excluded diffusers (4), maintaining an air flow per linear metre according to the design project which is such as not to generate ground currents and to obtain a diffusion of the air by inductive effect in the non-excluded first portion of the plant and a further sub-step of selecting one of the desired values. 
Postupak u skladu s prethodnim patentnim zahtjevom, naznačen time što korak odabira željene vrijednosti protoka zraka po linearnom metru uključuje podkorak određivanja željene vrijednosti protoka zraka po linearnom metru kod podešavanja radnih stanja postrojenja kada se upotrebljava postrojenje za grijanje okoliša, primjerice tijekom zime, i/ili podkorak određivanja željene vrijednosti protoka zraka po linearnom metru prema projektu dizajna kako ne bi došlo do generiranja podzemnih struja i kako bi se postiglo difundiranje zraka induktivnim učinkom, i/ili HR P20171943 T1 podkorak određivanja željene vrijednosti protoka zraka po linearnom metru u radnim stanjima uz pomoć jednog ili više isključenih difuzora (4), uz održavanje protoka zraka po linearnom metru prema projektu dizajna koji je takav da ne generira podzemne struje, te kako bi se postiglo difundiranje zraka induktivnim učinkom u neisključenom prvom dijelu postrojenja, zatim dodatni podkorak odabira jedne od željenih vrijednosti.
purifying the immunoglobulin with one or more chromatography steps, and providing an immunoglobulin solution, 
pročišćivanje imunoglobulina kroz jednu ili više kromatografskih faza, te pripremanje otopine imunoglobulina; d)
The gradient calculating unit 13 operates to the other band images in the same manner. As noted above, the gradient calculating unit 13 calculates the magnitude and the direction of the gradient of the pixel value for each pixel of the band images a, B, Y. 
(B) uređaj za izračun gradijenta (13) koji ima konfiguraciju za izračunavanje magnitude i smjera gradijenta (m) od vrijednosti piksela za svaki piksel u slici na traci (a, B, Y);
A method of forming a curable aqueous composition for a binder of nonwoven material, comprising the following steps: a step of combining (a) a hydroxy-containing polymer with (b) a multi-functional crosslinking agent which is at least one selected from the group consisting of a nonpolymeric polyacid and an anhydride, and optionally 
Postupak priprave učvršćujućeg vodenastog pripravka za vezivo netkanih materijala, naznačen time, da sadrži sljedeće korake: korak kombinacije (a) hidroksi-sadrživog polimera sa višefunkcionalnim sredstvom za križno spajanje, najmanje jedno izdvojeno iz grupe, koje se sastoji od nepolimernih poliacida i anhidrida, a po želji
The method of claim 1, comprising determining the presence of H-Ras mutation in a sample from said subject. The method of claim 6, wherein said sample is a tissue biopsy. The method of claim 6, wherein said sample is a tumor biopsy. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, pri čemu metoda sadrži utvrđivanje pristunosti H-Ras mutacije u uzorku uzetom od navedenog subjekta. Spoj za uporabu u skladu s patentnim zahtjevom 3, pri čemu je navedeni uzorak uzorak biopsije tkiva ili uzorak biopsije tumora.
In another embodiment, the present invention provides compounds of Formula (I) wherein n is 0; R1, R2, and R3 are hydrogen; and R6 is heteroarylalkyl. 
Naama RJ Spoj u skladu s patentnim zahtjevom I 7, naznačen time, da su R,, R2 i Rz vodik; nje 0;
An immunoconjugate of any of claims 1 to 9 for use in the treatment of cancer in a subject. 
Imunokonjugat iz bilo kojeg od patentnih zahtjeva 1 do 9 za uporabu u liječenju raka kod subjekta.
Process according to claim 1 or claim 2, wherein the cylinder oil produced comprises at least 10 % by weight used oil, based on the total amount of cylinder oil produced and/or at least 10 % by weight of fresh cylinder oil, based on the total amount of cylinder oil produced. 
Postupak prema zahtjevu 1 ili zahtjevu 2, naznačen time da proizvedeno cilindarsko ulje sadrži najmanje 10 % težinski rabljenog ulja, u odnosu na ukupnu količinu proizvedenog cilindarskog ulja ifili najmanje 10 % težinski svježeg cilindarskog ulja, u odnosu na ukupnu količinu proizvedenog cilindarskog ulja.
A core (1) according to claim 13, characterised in that it is made of PE (polyethylene)-based material. 
Jezgru (1), prema patentnom zahtjevu 12, naznačena time što je proizvedena od sirovine na bazi PE (polietilena).
a source of vacuum situated to be separated from the wound bed by the wound dressing; and 
- izvor vakuuma smješten da se odvaja od rane pomoću zavoja za rane; i
The vaccine according to any one of claims 1 to 4, for use according to claims 1 to 4 wherein the vaccine comprises from about 104.5 to about 107.0 TCID50/dose (50% tissue culture infective dose per dose of vaccine). 
Cjepivo prema bilo kojem od zahtjeva 1 do 4, naznačen time, da se upotrebljava prema zahtjevima 1 do 4, pri čemu cjepivo obuhvaća od oko 10% do oko 10%" TCIDso/doza (virusna doza koja je 50% inficirane kulture tkiva prema dozi cjepiva).
The aerosol for use of claim 1, wherein the solution consists essentially of a levofloxacin concentration of 90 mg/ml to 110 mg/ml, a magnesium chloride concentration of 180 mM to 220 mM, a pH of 5 to 7, an osmolality of 300 mOsmol/kg to 500 mOsmol/kg, and lacks lactose. 
Aerosol za uporabu sukladno patentnom zahtjevu 1, pri čemu se otopina u osnovi sastoji od koncentracije levofloksacina od 90 mg/ml do 110 mg/ml, koncentracije magnezij klorida od 180 mM do 220 mM, pH od 5 do 7, osmolalnosti od 300 mOsmol/kg do 500 mOsmol/kg, i nedostaje mu laktoza.
The pharmaceutically acceptable salt of the compound of claim 1, wherein the pharmaceutically acceptable salt is selected from succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, trifluoroacetic, malic, lactic, formic, propionic, glycolic, gluconic, camphorsulfuric, isothionic, mucic, gentisic, isonicotinic, saccharic, glucuronic, furoic, glutamic, ascorbic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), ethanesulfonic, pantothenic, stearic, sulfinilic, alginic, galacturonic, benzenesulfonic, p-toluenesulfonic, oxalic, methanesulfonic and naphthalenesulfonic acid salt. 
Farmaceutski prihvatljiva sol prema patentnom zahtjevu 2, naznačena time da je kiselina izabrana od sukcinske, maleinske, acetatne, fumarne, limunske, tartarne, benzojeve, trifluoroacetatne, jabučne, mliječne, mravlje, propionske, glikolne, glukonske, kamforsumporne, izotionske, mucinske, gentizinske, izonikotinske, šećerne, glukuronske, furoatne, glutaminske, askorbinske, antranilne, salicilne, fenilacetatne, mandelatne, embonske (pamoične), etansulfonske, pantotenske, stearinske, sulfanilinske, alginske, galakturonske, benzensulfonske, p-toluensulfonske, oksalne, metansulfonske i naftalensulfonske kiseline.
The lipid compound according to claim 2, wherein R2 and R3 each are independently chosen from a hydrogen atom, an ethyl group, a methoxy group, an ethoxy group, or a phenyl group; or R2 and R3 are connected to form a cyclobutane group. 
Lipidni pripravak prema zahtjevu 1, naznačen time da R> i R3 su neovisno odabrani od vodikovog atoma ili etilne skupine; ili R» i Rs su spojeni tako da tvore ciklobutansku skupinu.
The invention relates to an electrode compartment for an electrochemical cell, including a bicontinuous micro-eπulsion, wherein catalytic parts are generated in-situ in a fluid, which can act as a cathode as well as an anode. 
PATENTNI ZAHTJEVI M» nos Odjeljak elektrode za elektrokemijsku stanicu, koji sadrži bikontinuiranu mikroemulziju, pri čemu su katalitički dijelovi generirani in-situ u reakciji taloženja u navedenoj bikontinuiranoj mikroemulziji.
Glyceryl tri-[4-phenylbutyrate] (HPN-100) for use in a method of treating hepatic encephalopathy (HE) in a subject, wherein the method comprises: 
Gliceril tri-[4-fenilbutirat] (HPN-100) za uporabu u postupku liječenja jetrene encefalopatije (HE) kod subjekta, naznačen time da postupak obuhvaća:
vii) is a respiratory drug, an antiasthmatic agent, an analgesic agent, an antidepressant, an antianginal agent, an antiarrhythmic agent, an antihypertensive agent, an antidiabetic agent, an antihistamine, an anti-infective agent, an antibiotic, an antiinflamatory agent, an antiparkinsonism drug, an antipsychotics, an antipyretic agent, an antiulcer agent, an attention deficit hyperactivity disorder (ADHD) drug, a central nervous system stimulant, a decongestant, or a psychostimulant; 
vii) jest respiratorni lijek, antiasmatik, analgetik, antidepresiv, antianginozni lijek, antiaritmik, antihipertenziv, antidijabetik, antihistaminik, antiinfektiv, antibiotik, antiinflamatorni agens, antiparkinsonik, antipsihotik, antipiretik, antiulkusni agens, lijek za poremećaj pozornosti s hiperaktivnošću (ADHD), stimulans središnjeg živčanog sustava, dekongestiv, ili psihostimulans;
As = Absorbance of the sample EPMATHMARKEREP wherein: 
Broj objave europskog patenta:
In addition to this pre-clinical data, findings using inhibitory antibodies against EGFR and erbB2 (c-225 and trastuzumab respectively) have proven to be beneficial in the clinic for the treatment of selected solid tumours (reviewed in Mendelsohn et al, 2000, Oncogene, 19, 6550-6565). 
K- tome, rezultatima istraživanja u kojima su korištena inhibitorna antitijela protiv EGFR i erbB2 (c-225 i trastuzumab, respektivno) dokazana je korisnost takvih antitijela u kliničkom liječenju odabranih krutih tumora (pregledano u Mendelsohn i sur, 2000, Oncogene, 19, 6550-
The method of paragraph 53, wherein the persisting population of genetically engineered T cells comprises a memory T cell. 
T stanica za upotrebu prema patentnom zahtjevu 7, naznačena time što perzistentna populacija genetski modificiranih T stanica sadrži memorijsku T stanicu.
According to a preferred embodiment of the present invention the at least two fragments of PCSK9 (i.e. the at least two peptides derived from PCSK9) are coupled, individually or in combination, to a pharmaceutically acceptable carrier, preferably KLH (Keyhole Limpet Hemocyanin). 
Cjepivo prema bilo kojem od zahtjeva 1 do 5, naznačeno time, da su najmanje dva fragmenta od PCSK9 spojena na farmaceutski prihvatljiv nosač, poželjno na KLH (Keyhole Limpet Hemocyanin).
is -F or -C1-3perfluorinated alkyl; and R3 are each independently selected from the group consisting of halogen and -C1-5alkyl, or R2 and R3, taken together with the carbon atom to which they are attached, may form C3-6cycloalkyl (wherein C3-6cycloalkyl may be non-substituted, or substituted with halogen, -OC1-5alkyl or -C1-5alkyl); 
je -F ili -C1-3 perfluorirani alkil; ili R2 i R3, zajedno s atomom ugljika na koji su vezani, mogu tvoriti C3-6 cikloalkil (gdje C3-6cikloalkil mogu biti ne supstituirani ili supstituirani halogenom, -OC1-5 alkil ili -C1-5 alkil);
The composition according to claim 1, wherein the composition is a pharmaceutical composition comprising the GPR119 agonist and the DPP-IV inhibitor, together with at least one pharmaceutically acceptable carrier. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da pripravak je farmaceutski pripravak koji sadrži GPR119 agonist i DPP-IV inhibitor skupa s barem jednom farmaceutski prihvatljivom podlogom.
A method as claimed in Claim 11, wherein the solvent system of the inner coating preparation is aqueous. A method as claimed in Claim 11 or Claim 12, said method comprising dispersing a polycarboxylic acid polymer in a solvent, optionally with a buffer agent, and adding base to at least partially neutralise the polycarboxylic acid polymer to form the inner coating preparation. 
Postupak za koji se traži zaštita patentom u patentom zahtjevu 11 ili patentnom zahtjevu 12, spomenuti postupak sadrži disperziju polimera polikarboksilne kiseline u otapalu, izborno s puferskim sredstvom, i dodavanje baze da se barem delimično neutralizira polimer polikarboksilne kiseline da bi se formirao preparat unutarnje obloge.
The method according to claim 18, wherein the fibromatosis is selected from the group consisting of: palmar Dupuytren's contracture, La Peyronie's disease, Ledderhose's disease or plantar fascial fibromatosis, and retractable scars. 
Proizvod za uporabu u skladu s patentnim zahtjevom 16, naznačen time da je fibromatoza odabrana s popisa koji obuhvaća: palmarnu Dupuytrenovu kontrakturu, Peyronievu bolest, Ledderhoseovu bolest ili plantarnu ascijalnu fibromatozu ili uvučene ožiljke.
forming a first composition comprising the trans-(-)-A9-tetrahydrocannabinol from step (b), trans-(+)-A9-tetrahydrocannabinol, and a non-polar organic solvent. 
formiranje prvog sastava koji sadrži trans-(-)-A9-tetrahidrokanabinol iz koraka (b), trans-(+)-A9-tetrahidrokanabinol i nepolarno organsko otapalo.
In a third class of this embodiment, about 25% to about 100% by weight of the crystalline monohydrate is present in the drug substance. 
U trećoj klasi ove implementacije, oko 25% do 100% težinski kristalnog monohidrataje nazočno u supstanci lijeka.
The process for preparing the composition according to the invention can be carried out as a granulation process or a direct compression process. 
Postupak pripreme pripravka prema izumu može se provesti kao granulacijski postupak ili direktni postupak kompresije.
A pharmaceutical formulation comprising AMG 416 hydrochloride: in aqueous solution, wherein the formulation has a pH of 2.0 to 5.0. 
HR P20171092 T1 PATENTNI ZAHTJEVI 1. - Farmaceutska formulacija koja sadrži AMG 416 u vodenoj otopini, pri čemu formulacija ima pH od 2.0 do 5.0.
The amount of ET-743 (5.0 mg) was added to a compounding glass vessel and dissolved by magnetical stirring in ⅔ volume (60 ml) of the potassium phosphate solution for approximately 1 h (dissolution was checked visually). 
Količina ET-743 (5.0 mg) je dodana u staklenu posudu za miješanje i otopljena magnetnim miješanjem u 2/3 zapremini (60 ml) otopine kalijfosfata približno 1 sat (otapanje je provjeravano vizualno).
After 2 hours the reaction is poured onto ice-water (200 ml). 
Nakon 2 sata reakcijsku smjesu se prelije na led-vodu (200 ml).
wherein said linker (L) links (A) to (C). A pharmaceutical composition comprising the antibody or antigen binding fragment of claim 15 and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži antitijelo ili njegov antigen vezujući fragment iz bilo kojeg od patentnih zahtjeva 1-5, ili imunokonjugat iz bilo kojeg od patentnih zahtjeva 7-15 i farmaceutski prihvatljiv nosač.
A benzopyran derivative for use in the treatment of neuropathic pain, wherein the benzopyran derivative is represented by the following general formula, or a salt thereof, wherein R1 represents an optionally substituted C1-6 alkyl group; one of R2 and R3 represents a hydrogen atom; and the other of R2 and R3 represents a hydrogen atom, an optionally substituted amino group, an optionally substituted acylamino group, an optionally substituted carbamoyl group or an optionally substituted aryl group. 
O R o=s=0 R jedan od R2 i R3 predstavlja atom vodika, a drugi od R, i Rz predstavlja atom vodika, po izboru supstituiranu amino skupinu, po izboru supstituiranu acilamino skupinu, po izboru supstituiranu karbamoilnu skupinu ili po izboru supstituiranu arilnu skupinu.
the Fc domain exhibits reduced binding affinity to an Fc receptor and/or reduced effector function, as compared to a native IgG1 Fc domain; 
Fc domena pokazuje smanjeni afinitet vezivanja na Fc receptor i/ili smanjenu efektorsku funkciju, u usporedbi s izvornom IgG1 Fc domenom;
Enantiomeric compounds of the invention may be obtained (a) by the separation of the components of the corresponding racemic mixture, for example, by chiral chromatography, enzymatic resolution methods or preparing and separating suitable diastereoisomers, (b) by direct synthesis from the appropriate chiral starting materials by the methods described above, or (c) by methods analogous to those described above using chiral reagents. 
Enantiomerne spojeve prema ovom izumu može se dobiti (a) razdvajanjem komponenata odgovarajuće racemične smjese, primjerice kiralnom kromatografijom, postupcima enzimskog razdvajanja ili dobivanjem i razdvajanjem pogodnih dijasterecizomera, (b) izravnom sintezom iz odgovarajućih kiralnih polaznih materijala, postupcima opisanim gore, ili (c) postupcima analognim onima opisanim gore, uz upotrebu kiralnih reagensa.
The aqueous formulation of claim 2 comprising 0.1 µg to 10 µg lixisenatide per U insulin glargine, preferably 0.2 to 1 µg lixisenatide per U insulin glargine, more preferably 0.25 µg to 0.7 µg lixisenatide per U insulin glargine. 
Vodena formulacija u skladu s patentnim zahtjevom 4, naznačena time što sadrži 0,25 ug do 0,7 ug liksisenatida po jedinici inzulin glargina.
The solid oral extended release pharmaceutical dosage form of anyone of claims 1, 3, 5 and 7, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month contains an amount of the at least one active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation that deviates no more than about 10 % points from the corresponding amount of active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 16, naznačen time da formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25 °C i 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca sadrži količinu od najmanje jednog aktivnog sredstva u % (težinski) vezano uz deklaracijski zahtjev aktivnog sredstva za formulaciju matrice s produljenim otpuštanjem tako da odstupanje nije veće od oko 10 % točaka u odnosu na odgovarajuću količinu aktivnog sredstva u % (težinski) relativno prema deklaracijskom zahtjevu aktivnog sredstva za formulaciju matrice s produljenim otpuštanjem referentne formulacije prije pohranjivanja.
The solid dispersion of any one of Claims 1 to 3, wherein the dispersion polymer is hydroxypropyl methyl cellulose. 
Čvrsta disperzija u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je disperzijski polimer hidroksipropil(metil)celuloza.
In certain embodiments the invention is directed to a solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least: 
HR P20120613 T1 PATENTNI ZAHTJEVI Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem koji sadrži formulaciju matrice s produljenim otpuštanjem, te formulacija matrice s produljenim otpuštanjem sadrži pripravak koji sadrži barem: